arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Bodhi Tree Biotechnology Inc

BDTB
— Price unavailable
Industrials ·Services-Management Consulting Services ·USServices-Management Consulting Services
10 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Bodhi Tree Biotechnology Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin -232.0% ↘
ROIC -167.8% ↘
FCF / Share $-0.00 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

10-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.00K
↓ -33.3% —
Net Income Profit after all expenses
$-23.19K
↓ -11.6% —
Operating Margin Operating profit as % of sales
-232.0%
↓ -24.6% —
FCF / Share Free cash flow per share
$-0.00
↑ +23.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Cash Quality
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 6 days ago 2 years · 10 quarters